palmityl alcohol
Small moleculeexperimental
Cetyl alcohol is the 16-carbon alcohol corresponding to palmitic acid, so called because it is isolated from among the hydrolysis products of spermaceti. This medication is used as a moisturizer to treat or prevent dry, rough, scaly, itchy skin and minor skin irritations (e.g., diaper rash, skin burns from radiation therapy). Most emollients can be used safely and effectively with no side effects. However, burning, stinging, redness, or irritation may occur. A very serious allergic reaction to this drug is rare. — NCATS
Clinical trial activity
10 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
5
Earliest trial started Nov 1, 2006 (NCT00806221)
Timeline
Indications
Mechanism of action
- Unspecified targetOTHER
Surfactant
- Unspecified targetOTHER
Unknown
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCCO- Mol. weight
- 242.4406 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaCetyl alcohol ↗
- NCATS936JST6JCN ↗
- ChEMBLCHEMBL706 ↗
Also known as
- 1-hexadecanol
- 1-hexadecanol
- cetaffine
- cetanol
- cetanol
- cetanol
- cetanol
- cetaphil
- cetaphil
- cetyl alcohol
- cetyl alcohol
- cetyl alcohol
- cetyl alcohol
- cetyl alcohol
- cetyl alcohol
- cetyl alcohol
- cetyl alcohol
- cetyl alcohol, 14c-labeled
- cetyl alcohol, aluminum salt
- cetylic alcohol
- cetylol
- hexadecan-1-ol
- hexadecanol
- hexadecanol
- n-hexadecanol
- palmitic alcohol
- palmityl alcohol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03151148 | Phase 1/Phase 2 (Phase 2) | Jun 16, 2017 | Atopic Dermatitis Research Network, National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Diego |
| NCT02589405 | Phase 4 | Aug 1, 2015 | Galderma, Proinnovera GmbH |
| NCT02218463 | N/A | Sep 1, 2014 | University of Kansas, University of Missouri, University of Missouri, Kansas City |
| NCT02249104 | Phase 4 | Aug 1, 2014 | Galderma, Pflugerville Dermatology Clinical Research |
| NCT03037541 | Phase 3 | Jan 5, 2011 | Wake Forest University |
| NCT01142999 | N/A | May 1, 2010 | Oregon Health and Science University |
| NCT00971282 | Phase 4 | Dec 1, 2008 | Galderma |
| NCT00669071 | Phase 4 | Jan 1, 2008 | Galderma |
| NCT00806221 | Phase 2 | Nov 1, 2006 | Galderma, National Eczema Association, Oregon Health and Science University |
| NCT00693654 | Phase 4 | Nov 1, 2006 | GlaxoSmithKline, Wake Forest University |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galderma | For profit | 5 | 4 | 2 | 2006 |
| Oregon Health and Science University | Academic/Hospital | 2 | 2 | 2 | 2006 |
| Wake Forest University | Academic/Hospital | 2 | 2 | 2 | 2006 |
| Atopic Dermatitis Research Network | Academic/Hospital | 1 | 0 | 1 | 2017 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2006 |
| National Eczema Association | Academic/Hospital | 1 | 0 | 1 | 2006 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2017 |
| Pflugerville Dermatology Clinical Research | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Proinnovera GmbH | For profit | 1 | 0 | 1 | 2015 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Missouri | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Missouri, Kansas City | Academic/Hospital | 1 | 0 | 1 | 2014 |
13 organizations
Page 1 / 1